About RxCelerate
RxCelerate is a Healthcare company based in Babraham (United Kingdom) founded in 2012. Pre-clinical contract research services are offered for drug candidates. RxCelerate has completed 4 acquisitions, including Methuselah Health, Prosarix and The Cambridge Partnership. RxCelerate offers products and services including In Silico Drug Design, Antibody Discovery Platform, and Proteomics Platform. Its focus areas include Biopharma Outsourcing, CRO, Preclinical Studies and Diversified. Its legal entity is RXCELERATE LIMITED. Its competitors include Gentronix and Aquila BioMedical.
Company details
Founded in 2012 and based in Babraham, United Kingdom, RxCelerate operates in the biotechnology sector. Pre-clinical contract research services are provided to advance lead candidates from discovery to IND readiness. Key offerings include GLP efficacy studies, toxicology assessments, and ADME evaluations, supporting pharmaceutical development processes.
- Headquarters Babraham, United Kingdom
- SectorsHealthcare
- Email••••••••
- Website rxcelerate.com
- Social LinkedIn X YouTube
- Legal Name Rxcelerate Limited
- Date of Incorporation 07 Nov, 2012
- Jurisdiction CAMBRIDGE, ENGLAND
- Investments & AcquisitionsMethuselah Health
& 3 more
Products & Services of RxCelerate
RxCelerate offers a comprehensive portfolio of products and services, including In Silico Drug Design, Antibody Discovery Platform, and Proteomics Platform.
Computational platform for designing small molecule drugs.
Service for rapid identification of antibody leads.
Tool for protein analysis in drug development.
Apps and channels of RxCelerate
its YouTube channel RxCelerate has 45 subscribers and 5 videos.
Videos from RxCelerate
The most watched videos on RxCelerate's YouTube channel, RxCelerate (45 subscribers). Click a video to play it here.
More on RxCelerate.
Funding Insights of RxCelerate
- Total Rounds 1
All 1 funding rounds of RxCelerate with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2024 | Seed | – | – | – |
People of RxCelerate
22 people are tracked at RxCelerate (11 in leadership, 11 in team).
| Name | Role | Group |
|---|---|---|
Melanie Medcalf | Director Of Facilities And Laboratory Operations | Leadership |
Gundeep Singh | Director Of Project Management | Leadership |
Jill Reckless | CEO | Leadership |
Sharon Williams | VP Operations | Leadership |
Rachel Watson | Director Of Preclinical Operations And Scientfic Programmes | Leadership |
Andrew Carr | Director Of Chemistry Operations | Leadership |
David Mosedale | VP - Proquant | Leadership |
Donna Leach (Assoc. Cipd | Head Of Human Resources | Leadership |
Nick Tait | Group CFO | Leadership |
Joao Victor de Souza | Head Of Molecular Modelling | Leadership |
Inês Barbosa | Head Of Portfolio Management | Leadership |
Natalie Church | Senior Project Manager | Team |
Deborah Chell | Environment, Health And Safety Manager | Team |
Danuta Long | Quality Assurance Officer | Team |
Sanchari Roy | Senior Scientist/ Project Leader | Team |
Eleanna Stamatakou | Senior Scientist | Team |
Matthew Earl | Chemistry Project Leader | Team |
Jennifer Hillman | In Vitro Team Leader | Team |
Raul de la Flor | Senior R&d Project Manager | Team |
Molly McDonald | Senior HR & Talent Acquisition Co-ordinator | Team |
2 more people are available in the full profile.
Complete people profiles for RxCelerate
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by RxCelerate
RxCelerate has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Methuselah Health, Prosarix and The Cambridge Partnership.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Novel targets for aging-related diseases are developed via proteome research. | methuselah-health.com | Babraham, United Kingdom | 2015 | Nov 2022 | •••• | |
Computational drug discovery company with proprietary platform for small molecule screening and design | prosarix.com | Cambridge, United Kingdom | 2006 | Feb 2019 | •••• | |
Infrastructure and management services for virtual biotech companies are provided. | thecambridgepartnership.com | Cambridge, United Kingdom | 2013 | May 2018 | $1.96M | |
Biomarker discovery and validation services for industry and academia | totalscientific.com | Cambridge, United Kingdom | 2006 | Apr 2018 | •••• |
Complete acquisition details for RxCelerate
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of RxCelerate
7 dated milestones of RxCelerate across 12 years, from founding to its latest funding, stage changes and deals.
- Founded RxCelerate is founded.
- Acquisition Acquires Total Scientific.
- Acquisition Acquires The Cambridge Partnership.
- Acquisition Acquires The Cambridge Partnership.
- Acquisition Acquires Prosarix.
- Acquisition Acquires Methuselah Health.
- Funding First funding round.
Competitors of RxCelerate
RxCelerate has 2 listed competitors in our database. They include Gentronix and Aquila BioMedical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gentronix.co.uk | 1999 | Alderley Edge, United Kingdom | 1 | In-vitro and in-vivo genetic toxicology screening services are provided. | ||
| aquila-bm.com | 2011 | Edinburgh, United Kingdom | 489 | Preclinical services in immunology, regeneration, neuroscience, and histology are provided. |
Detailed competitors of RxCelerate
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of RxCelerate
The website of RxCelerate (rxcelerate.com) receives about 1.5K visits a month.
- Monthly visits1.5K
▲ 1.5% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rxcelerate
Complete news archive for RxCelerate
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about RxCelerate
RxCelerate was founded in 2012 and raised its 1st funding round 12 years after it was founded.
RxCelerate is headquartered in Babraham, United Kingdom. It is registered at Babraham, Cambridgeshire, United Kingdom.
Founded in 2012 and based in Babraham, United Kingdom, RxCelerate operates in the biotechnology sector. Pre-clinical contract research services are provided to advance lead candidates from discovery to IND readiness. Key offerings include GLP efficacy studies, toxicology assessments, and ADME evaluations, supporting pharmaceutical development processes.
RxCelerate's top competitors include Gentronix and Aquila BioMedical.
RxCelerate offers In Silico Drug Design, Antibody Discovery Platform, and Proteomics Platform.
RxCelerate has made 4 acquisitions, including Methuselah Health, Prosarix, and The Cambridge Partnership.
RxCelerate operates through Rxcelerate Limited.